Stifel Assumes Lumos Pharma (LUMO) at Buy

March 11, 2021 7:18 AM EST
Get Alerts LUMO Hot Sheet
Price: $12.06 +7.30%

Rating Summary:
    7 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 18 | Down: 8 | New: 31
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Stifel analyst Derek Archila assumes coverage on Lumos Pharma (NASDAQ: LUMO) with a Buy rating and a price target of $24.00.

The analyst comments "We think the premise of an oral therapy for pediatric growth hormone deficiency (PGHD) vs. an injectable one is enticing and think LUM-201, an oral GH secretagogue, could offer PGHD patients with a functioning HP-GH axis this benefit. We like management's patient enrichment approach for enrolling the ongoing Ph2 study, expected to read out in mid-2022, and responses rivaling that of daily injectable rGH we think is enough to confirm this approach in a subsequent Ph3 trial. With the stock effectively trading at cash, we think it reflects investor concerns around LUM-201's long history when developed by MRK. Our review of the available data gets us comfortable on LUM-201's potential efficacy in PGHD based on relevant biomarkers associated with GH levels and that most safety issues were seen in elderly patients. We think shares trade up ahead of results next year and would be buyers at these levels."

For an analyst ratings summary and ratings history on Lumos Pharma click here. For more ratings news on Lumos Pharma click here.

Shares of Lumos Pharma closed at $13.25 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities